Short- and long-term effects of dapagliflozin as an adjunct to insulin therapy in diabetic dogs: A pilot study
This pilot study demonstrates that adjunctive dapagliflozin therapy in insulin-treated diabetic dogs significantly improves short- and long-term glycemic control and reduces specific metabolic and cardiovascular markers with a generally favorable safety profile, despite requiring dietary adjustments to manage weight loss.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For dogs diagnosed with diabetes, the path to health is a narrow and demanding one. Unlike humans who might manage the condition with diet or pills, nearly every dog with diabetes lacks the ability to produce insulin, the hormone that allows the body to use sugar for energy. Without this hormone, sugar builds up in the blood, leading to severe illness or death. Consequently, these animals rely entirely on daily insulin injections to survive, a regimen that mimics the treatment for a specific type of human diabetes. While modern insulin has improved, keeping blood sugar levels steady remains a difficult balancing act for many owners and veterinarians. When sugar levels swing too high, the dog suffers; when they swing too low, the dog faces immediate danger. This constant struggle has led researchers to look for new tools, specifically a class of drugs that help the body remove excess sugar through urine. These drugs, known as SGLT2 inhibitors, have been used in humans for years, but their safety and effectiveness in dogs, who are already dependent on insulin, had never been thoroughly tested.
A team of researchers at the Federal University of Rio Grande do Sul in Brazil decided to explore this possibility in a small group of diabetic dogs. They wanted to see if adding a specific drug called dapagliflozin to the standard insulin treatment could help stabilize blood sugar without causing harm. The study involved six dogs of various breeds, all of whom were already receiving insulin injections. The researchers introduced a liquid form of dapagliflozin, giving the dogs a dose of roughly 0.09 milligrams per kilogram of body weight once a day. Over a period of 100 days, the team monitored the dogs closely, tracking their blood sugar levels continuously with a sensor worn on the skin, and regularly checking their weight, blood pressure, and various chemical markers in their blood and urine.
The results of this short-term and long-term observation were encouraging. In the days immediately following the start of the treatment, the dogs' average blood sugar levels dropped significantly. The peaks of high sugar became lower, and the lowest points did not fall dangerously low. Most importantly, the dogs spent more time with their blood sugar in the healthy target range and less time in the dangerous high range. The treatment did not cause the dogs to experience clinical low blood sugar, a condition where an animal becomes weak or collapses, nor did it lead to a dangerous buildup of ketones, which can cause a life-threatening condition called diabetic ketoacidosis. However, the researchers did notice that the blood sugar levels fluctuated more than before, a change that required careful monitoring.
As the study progressed over the full 100 days, the benefits extended beyond just blood sugar control. The dogs showed improvements in several other health markers. Their blood pressure decreased, and levels of certain liver enzymes and cholesterol in their blood went down, suggesting a positive effect on their overall metabolism. One notable side effect was that three of the six dogs lost weight unintentionally. To counteract this, the owners increased the amount of food these dogs ate by about 25 percent, which successfully managed the weight loss. The researchers also adjusted the dosage of the dapagliflozin for most of the dogs; they lowered the dose for four dogs because the sugar levels were getting too low, increased it for one, and kept it the same for another. Despite these adjustments, the amount of insulin the dogs received remained largely unchanged throughout the study.
The study found no signs of urinary tract infections, electrolyte imbalances, or other serious complications that sometimes accompany this type of medication in humans. The dogs did not develop diabetic ketoacidosis, and their urine showed no signs of infection. While the sample size was small and the study was not a large-scale clinical trial, the findings suggest that adding dapagliflozin to insulin therapy is a safe and effective way to improve blood sugar control in diabetic dogs. The treatment appeared to be well-tolerated, offering a potential new option for veterinarians and owners who struggle to keep their diabetic pets' sugar levels stable. This pilot study provides a foundation for further research, indicating that this approach could become a valuable part of managing diabetes in dogs, much like it has for some people.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.